Given this correlation, as well as the number of tau-based therapies being developed (Boutajangout et al. 2011; Panza et al. 2016), a tau PET imaging agent would allow for the selection of tau-positive AD patients for enrollment in clinical trials of such experimental treatments, and provide a means to monitor response to therapy. The gene discussed is MAPT; the disease is Alzheimer disease.